A Study to Determine Dose and Regimen of Durvalumab as Monotherapy or in Combination With Pomalidomide With or Without Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma
Completed
This is a multicenter, open-label, Phase 1b study to determine the recommended dose and regimen of durvalumab either as monotherapy or in combination with POM with or without low dose dex in subjects with RRMM. The study will consist of a dose-finding portion as well as a parallel dose-expansion portion to determine the optimal dose and regimen. On 05 Sep 2017, a Partial Clinical Hold was placed on this study by the United States (US) Food and Drug Administration (FDA). The decision by the FDA... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/03/2024
Locations: Local Institution - 102, Baltimore, Maryland +21 locations
Conditions: Multiple Myeloma
Post-operative Course of Dexamethasone to Reduce Tonsillectomy Morbidity
Terminated
The goal of this study is determine if an oral systemic course of steroids is a safe and effective option in lowering pain and complications following adenotonsillectomy in various pediatric age groups. A double blind, placebo-controlled randomized clinical trial of steroids (dexamethasone) versus placebo postoperatively will be performed. Investigators will determine if there is a difference in post-operative pain and complications between groups.
Gender:
ALL
Ages:
Between 3 years and 17 years
Trial Updated:
08/29/2024
Locations: UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania +1 locations
Conditions: Adenotonsillectomy, Analgesia, Surgery
A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
Terminated
The purpose of this clinical trial is to learn how the experimental medicine maplirpacept (PF-07901801) affects people with various types of blood cancers: * relapsed or refractory (R/R) lymphoma * multiple myeloma * newly diagnosed acute myeloid leukemia (AML). This trial will be conducted in the outpatient setting in 2 parts, phase 1a and phase 1b. You may only participate in one part of the study. During phase 1a of this study, we will explore how much maplirpacept (PF-07901801), when used... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/29/2024
Locations: Keck Hospital of USC, Los Angeles, California +61 locations
Conditions: Lymphoma, Multiple Myeloma, Acute Myeloid Leukemia, Diffuse Large B-Cell Lymphoma
Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma
Completed
This phase I/II trial studies the side effects and best dose of idasanutlin and ixazomib citrate when given together with dexamethasone in treating patients with multiple myeloma that has returned after a period of improvement. Drugs used in chemotherapy, such as idasanutlin and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ixazomib citrate may stop the growth of cancer ce... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/27/2024
Locations: City of Hope Comprehensive Cancer Center, Duarte, California +7 locations
Conditions: Loss of Chromosome 17p, Recurrent Plasma Cell Myeloma
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
Recruiting
The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of oral cemsidomide (also known as CFT7455) administered at different dosages in subjects with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM). Cemsidomide may be administered as a single agent and, in MM only, in combination with oral dexamethasone.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/27/2024
Locations: Mayo Clinic, Phoenix, Arizona +12 locations
Conditions: Multiple Myeloma, Lymphoma, Non-Hodgkin's
Exparel v Dexamethasone in RCR
Enrolling By Invitation
Effective and safe control of pain after shoulder surgery is an important component of the post-surgical process. Patients who are comfortable in the early period after surgery are more satisfied with their experience and are better able to participate in rehabilitation exercises during their stay in the hospital. As surgeons and health care systems in the United States find themselves in the middle of an opioid epidemic, it is necessary to discover different options to provide patients pain rel... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/26/2024
Locations: Rothman Orthopaedic Institute, Philadelphia, Pennsylvania
Conditions: Rotator Cuff Tears, Postoperative Pain
Efficacy of Opioid-limiting Pain Management Protocol in Men Undergoing Urethroplasty
Completed
The investigator's study aims to see if an enhanced recovery regimen of pain medications before and during surgery will decrease the use and risk of opioid pain medications as well as improve pain control in anterior urethroplasty patients. Participants will be randomized to one of two pain regimens (enhanced recovery regimen vs standard regimen).
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/23/2024
Locations: University of Alabama of Birmingham, Birmingham, Alabama
Conditions: Pain, Postoperative, Urethral Stricture
Carfilzomib With Bendamustine and Dexamethasone in Multiple Myeloma
Terminated
This study is designed to define dose-limiting toxicity and determine preliminary evidence of efficacy of carfilzomib (CFZ) in combination with bendamustine and dexamethasone for patients with newly diagnosed multiple myeloma (MM).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/20/2024
Locations: Columbia University Irving Medical Center, New York, New York
Conditions: Multiple Myeloma
The Effect of IV NSAID's and Corticosteroids on Dysphasia and Dysphonia Following ASDF
Terminated
This study is to assess the efficacy of intra-operative intravenous non-steroidal anti-inflammatory drug (Ketorolac) versus intravenous (dexamethasone) administration on dysphagia and dysphonia after anterior cervical discectomy and fusion (ACDF).
Gender:
ALL
Ages:
19 years and above
Trial Updated:
08/20/2024
Locations: University of Nebraska Medical Center, Lauritzen Outpatient Center, Omaha, Nebraska
Conditions: Dysphagia, Dysphonia
An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients With Multiple Myeloma
Completed
The purpose of this study is to determine the side effects of treatment of the combination of nivolumab and daratumumab in participants with relapsed/refractory multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/13/2024
Locations: Local Institution - 0035, Clovis, California +42 locations
Conditions: Non-Hodgkin's Lymphoma, Hodgkin Lymphoma, Multiple Myeloma
A Study Comparing Once-weekly vs Twice-weekly Carfilzomib in Combination With Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
Completed
Compare efficacy of 56 mg/m2 carfilzomib administered once-weekly in combination with lenalidomide and dexamethasone (KRd 56 mg/m2) to 27 mg/m2 carfilzomib administered twice-weekly in combination with lenalidomide and dexamethasone (KRd 27 mg/m2) in subjects with relapsed or refractory multiple myeloma (RRMM) with 1 to 3 prior lines of therapy.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
08/09/2024
Locations: Robert A Moss Oncology, Fountain Valley, California +107 locations
Conditions: Relapsed or Refractory Multiple Myeloma
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Recruiting
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spread... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2024
Locations: Anchorage Associates in Radiation Medicine, Anchorage, Alaska +599 locations
Conditions: Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma